Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting ...
Certara provides scientists with automated, comprehensive tools for PK/PD analysis and modeling, and announces industry’s first PK/PD certification program for Phoenix software in partnership with ...
PRINCETON, NJ--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the ...
Certara, the global model-informed drug development and decision support leader, announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) modelling ...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback